Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 11/20 | 0.68 |
| ▸ | OXTR | P30559 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623456 | 0.83 | AVPR2 (0.77) | AVPR2AVPR1AOXTR | |
| SCHEMBL6627050 | 0.81 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL6623504 | 0.80 | AVPR2 (0.76) | AVPR2AVPR1AOXTRCYP3A4CYP2C19 | |
| SCHEMBL6624422 | 0.79 | AVPR2 (0.73) | AVPR2AVPR1AOXTRCYP3A4CYP2C19 | |
| SCHEMBL6624625 | 0.76 | AVPR2 (0.68) | AVPR2AVPR1AOXTR | |
| SCHEMBL14130377 | 0.75 | AVPR2 (0.66) | AVPR2AVPR1AOXTRCYP3A4CYP2C19 | |
| SCHEMBL6618394 | 0.74 | AVPR2 (0.71) | AVPR2AVPR1AOXTRCYP3A4CYP2C19 | |
| SCHEMBL6615751 | 0.74 | AVPR2 (1.00) | AVPR2AVPR1AOXTRCYP3A4CYP2C19 | |
| SCHEMBL17158263 | 0.74 | AVPR2 (0.69) | AVPR2AVPR1AOXTRCYP3A4CYP2C19 | |
| SCHEMBL14130132 | 0.73 | AVPR2 (0.60) | AVPR2AVPR1AOXTRCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | claimed |
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | disclosed |